Clinical Commissioning Policy: Canakinumab for treating periodic fever syndromes: TRAPS, HIDS/MKD and FMF (ages 2 years and older)

NHS England will commission canakinumab for treating periodic fever syndromes: Tumour necrosis factor receptor associated periodic syndrome, hyperimmunoglobulin D syndrome/mevalonate kinase deficiency and familial Mediterranean fever in accordance with criteria specified.

Source:

NHS England